Amgen Inc. (NASDAQ:AMGN) Shares Sold by Fulton Bank N.A.

Fulton Bank N.A. lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.3% during the first quarter, Holdings Channel.com reports. The fund owned 17,611 shares of the medical research company’s stock after selling 229 shares during the period. Fulton Bank N.A.’s holdings in Amgen were worth $5,487,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Tallon Kerry Patrick acquired a new stake in shares of Amgen in the fourth quarter valued at $270,000. Brighton Jones LLC lifted its holdings in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Heck Capital Advisors LLC acquired a new stake in Amgen in the 4th quarter valued at about $36,000. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Amgen by 2.1% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 15,728 shares of the medical research company’s stock valued at $4,099,000 after purchasing an additional 316 shares in the last quarter. Finally, McAdam LLC grew its stake in shares of Amgen by 5.9% in the 4th quarter. McAdam LLC now owns 856 shares of the medical research company’s stock worth $223,000 after purchasing an additional 48 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.1%

Amgen stock opened at $288.47 on Tuesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market cap of $155.11 billion, a PE ratio of 38.21, a P/E/G ratio of 2.63 and a beta of 0.51. The firm’s 50 day moving average price is $283.12 and its two-hundred day moving average price is $285.27.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the prior year, the business posted $3.96 earnings per share. Amgen’s revenue for the quarter was up 9.4% compared to the same quarter last year. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on AMGN shares. Erste Group Bank lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Citigroup reissued a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Cantor Fitzgerald initiated coverage on Amgen in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 target price on the stock. Finally, Johnson Rice set a $294.00 price target on Amgen in a research report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus target price of $309.22.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.